Details

Autor(en) / Beteiligte

• Chen, Po-Yu Jay
• Rossin, Elizabeth J
• Vavvas, Demetrios G

Titel

Aflibercept for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis

Ist Teil von

• Ophthalmic surgery, lasers & imaging retina, 2021-12, Vol.52 (12), p.673

Ort / Verlag

United States

Erscheinungsjahr

2021

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• To determine the effectiveness of aflibercept in retinopathy of prematurity (ROP). We performed a systematic review and meta-analysis of proportions from the literature in PubMed and Cochrane Library using search terms related to the use of aflibercept in ROP. Studies in non-preterm infants or that did not use aflibercept as the initial treatment were excluded. Risk of bias was assessed by the ROBINS-I (Risk Of Bias in Non-randomized Studies of Interventions) tool. We identified six case series. Collectively, 218 eyes were treated with aflibercept for ROP. We found an average 97% (95% confidence interval [CI], 93% to 99%) regression rate with aflibercept and an average 16% (95% CI, 5% to 41%) recurrence rate. With the exception of one outlier study, these numbers are similar to previous reports using anti-vascular endothelial growth factor (VEGF) agents in ROP. Aflibercept holds promise for use in ROP and has been demonstrated to be efficacious in six case series. Randomized, controlled clinical trials appear warranted to compare aflibercept with other anti-VEGF agents. .